Beyondspring (NASDAQ:BYSI) Rating Reiterated by HC Wainwright
HC Wainwright reiterated their buy rating on shares of Beyondspring (NASDAQ:BYSI) in a research report report published on Wednesday, Briefing.com Automated Import reports. They currently have a $60.00 price target on the stock.
Separately, Maxim Group reiterated a buy rating and issued a $58.00 target price on shares of Brinker International in a report on Tuesday, April 30th.
NASDAQ:BYSI traded down $0.27 on Wednesday, hitting $19.80. The stock had a trading volume of 18,257 shares, compared to its average volume of 27,444. The firm has a market capitalization of $444.23 million, a PE ratio of -8.18 and a beta of 1.39. The stock has a fifty day moving average price of $19.09. Beyondspring has a 1-year low of $13.06 and a 1-year high of $27.53.
Beyondspring Company Profile
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
Recommended Story: Moving Average (MA)
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.